Oruka Therapeutics (NASDAQ:ORKA) Stock Price Expected to Rise, BTIG Research Analyst Says

Oruka Therapeutics (NASDAQ:ORKA) had its price target lifted by analysts at BTIG Research from $44.00 to $56.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price would suggest a potential upside of 237.76% from the stock’s previous close.

A number of other research firms also recently weighed in on ORKA. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Monday, August 18th. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. Finally, Wedbush restated an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. According to data from MarketBeat, Oruka Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $42.00.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $16.58 on Wednesday. The company has a market cap of $620.94 million, a P/E ratio of -5.90 and a beta of -0.26. The stock’s fifty day moving average price is $14.78 and its two-hundred day moving average price is $12.15. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.02. On average, analysts expect that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ORKA. Jane Street Group LLC bought a new stake in shares of Oruka Therapeutics in the fourth quarter worth about $343,000. Millennium Management LLC bought a new stake in shares of Oruka Therapeutics in the fourth quarter worth about $588,000. Squarepoint Ops LLC bought a new stake in shares of Oruka Therapeutics in the fourth quarter worth about $236,000. Northern Trust Corp bought a new stake in shares of Oruka Therapeutics in the fourth quarter worth about $1,242,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the first quarter worth about $1,362,000. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.